Impacts of loading thymoquinone to gold or silver nanoparticles on the efficacy of anti-tumor treatments in breast cancer with or without chemotherapeutic cisplatin

Table 2 Changes in the total number of the leucocyte indices and the absolute number of their differentials in EAC tumor-bearing mice receiving CP, TQ, AuNPs, AgNPs AuNPs/TQ, AgNPs/TQ, AuNPs/TQ + CP, and AgNPs/TQ + CP

Treatments	WBCs count (× 10³)	Leucocytes differentials relative number (%)
Treatments	WBCs count (× 10³)	Lymphocytes	Neutrophils	Monocytes
Naïve	4800.0 ± 1069	4668.30 ± 1065	96.0 ± 21.4	25.67 ± 13.74
PBS	4633.3 ± 294	4525.67 ± 240	61.3 ± 14.5	46.33 ± 2.40
CP	4500.0 ± 945	4328.00 ± 947	107.0 ± 39.5	51.33 ± 36.93
TQ	5466.7 ± 1633	5310.70 ± 1626	91.0 ± 2.5	54.67 ± 16.33
AuNPs	7933.3 ± 966	6064.00 ± 253	1033.0 ± 331a, b,c	569.33 ± 228b, c
AgNPs	7100.0 ± 1159	7755.00 ± 303	307.0 ± 105	152.67 ± 56.1
AuNPs/TQ	6166.7 ± 1364	5855.00 ± 1255	250.0 ± 96.4	61.67 ± 13.64
AgNPs/TQ	5133.0 ± 785	4446.60 ± 810	520.6 ± 66	102.67 ± 15.72
AuNPs/TQ + CP	5666.7 ± 1328	5231.30 ± 1146	295.3 ± 136	113.33 ± 26.57
AgNPs/TQ + CP	3666.0 ± 775	3484.00 ± 767	92.6 ± 6.6	54.67 ± 14.50

Data are postulated as mean ± SE (n = 5). A statistically significant difference between the groups was established at P < 0.05. ^{a, b,c} indicate statistically significant differences, when compared to the naïve mice group (a), EAC tumor-bearing mice receiving PBS (b), EAC tumor-bearing receiving CP (c)

ISSN: 1472-6750